Edition:
United Kingdom

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®


Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Trovagene Inc ::TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.TROVAGENE INC - ‍LOOKING FORWARD TO A DECISION FROM FDA PERMITTING STUDY TO PROCEED, INITIATING MCRPC CLINICAL TRIAL IN PROSTATE CANCER IN 2018​.